Takeda Pharmaceuticals debuts at CIIE with two new lung cancer products

Shanghai, November 9th, 2021/PRNewswire/ - On November 7, 2021, Takeda Pharmaceuticals held a special launch conference for lung cancer of the "Double Stars" and "Two Stars", Mobocertinib, two new lung cancer treatment drugs known as "Lung Cancer Double Stars" Brigatinib and Brigatinib made their debut in the Expo, opening the prelude to Takeda's entry into China's lung cancer treatment field, bringing new hope to patients with rare targets in the lung cancer field

Picture: Guests witnessed the debut of Takeda's "Lung Cancer Double Star"

Lung cancer ranks first in the incidence of malignant tumors in China [1], and is one of the major challenges facing cancer prevention and treatment in China

Take EGFR exon 20 insertion mutation as an example.

Another type of ALK fusion-positive patients often face the problem of brain metastases.

Picture: Professor Zhou Caicun introduced the current status of lung cancer diagnosis and treatment in China

Professor Zhou Caicun, Chairman of the Chinese Society of Clinical Oncology (CSCO) Non-Small Cell Lung Cancer Expert Committee and Director of the Oncology Department of Shanghai Pulmonary Hospital Affiliated to Tongji University, said: “As a medical professional in the field of lung cancer treatment, I am very happy to see With the support of all parties, more and more innovative treatment options can be introduced into China at the first time, bringing new hope to patients with rare targets of lung cancer, helping China's lung cancer diagnosis and treatment level to be in line with international standards, and promoting the development of the industry

While accelerating the introduction of innovative products, Takeda is also actively committed to promoting the popularization of precision diagnosis and treatment of lung cancer

Picture: Takeda Lung Cancer Diagnosis and Treatment Alliance Inauguration Ceremony

"It is an honor to be able to share global innovation experience and achievements through the platform of the 4th CIIE, showing Takeda's long-term and deep cultivation on the road of exploring core areas such as lung cancer, and promoting the development of the health industry

Approval number: C-ANPROM/CN/788/0013

Approval date: 2021.

About Takeda Pharmaceutical

Takeda Pharmaceutical (Tokyo Stock Exchange: 4502) (New York Stock Exchange: TAK) is a global biopharmaceutical company headquartered in Japan, based on values ​​and driven by R&D

Takeda entered China in 1994.

For more information, please visit https:// hint

For the purposes of this article, "press release" refers to this document, any oral statement, any question-and-answer session, and any written or oral materials discussed or distributed by Takeda Pharmaceutical Co.

Companies directly or indirectly held by Takeda through investment are independent entities

Forward-looking statements

This press release and any materials distributed in connection with it may contain forward-looking statements, views or opinions related to Takeda’s future business, future conditions and operating performance, including Takeda’s estimates, forecasts, goals and plans

[1] https://gco.

[2] Liu ZF, et al.

[3] Costa DB, et al.

Source: Takeda China